To address the impact of exogenous TPO on in vivo induction of iKMT2A-MLLT3-driven AML, we harvested BM cells 48 h after a single TPO injection and transplanted equal numbers (103) of naïve (CD45.2+) KME LT-HSC or MPP1 into lethally irradiated (CD45.1+) wildtype recipients (Fig. 2D). The gene discussed is MLLT3; the disease is acute myeloid leukemia.